NIH's Role In Sustaining the U.S. Economy 2021 Update Now Available here
UMR Urges House and Senate Leaders to Include NIH Funding in COVID Relief Package read here
UMR releases new fact sheets on COVID-19 and biomedical research. Read here
See how UMR members are aiding in the fight against the coronavirus here
A new episode of the Amazing Things Podcast is now available! Check it out here.

A participant in the NIH 2019-2020 Medical Research Scholars Program.

Photo Credit: National Institutes of Health

About This Photo

A Power Boost for COVID-19 Clinical Trials

More than 3,000 COVID-19 clinical trials have launched in the past year. That sounds like good news, but many of these are ill-suited for identifying interventions that save lives. Bloomberg School researchers have responded with strategies that can better distinguish clinically meaningful signals from confounding statistical noise.

Many COVID-19 trials have too small a sample size, and thus lack the “statistical power” to confidently determine whether patients are responding to treatment, says Elizabeth Ogburn, an associate professor in the Department of Biostatistics. Such underpowered trials may not have enough participants to produce a measurable effect from therapy; they may also yield false-positive results if a few patients’ conditions improve by chance rather than in response to treatment.